Sentence examples for entry into a study from inspiring English sources

The most important reasons for failing entry into a study remain lack of an adequate trial and unmet inclusion criteria.

Survival was a secondary end point as patients who progressed on the placebo arm were allowed to crossover to low-dose bevacizumab or entry into a study of bevacizumab in combination with thalidomide.

Although their overall recruitment rate was 19%, no trials were available for 40% of patients, 32% of patients were ineligible, and 19% of eligible patients declined entry into a study.

However, the value of these distinctions is unclear.Three hundred eighty-five women with full or partial AN, BN, or BED were assessed at entry into a longitudinal study of eating disorders.Stepwise discriminant analysis revealed that full and partial BN were discriminated by the Yale-Brown-Cornell Eating Disorders Scale total scores (kappa =.46).

In real life, the time of zero is at entry into a clinical study, and it is unrealistic to imagine that at exactly that instant, the hazard of an event such as death plunges to zero.

The aim of this study was to evaluate the physician patient communication process during the cancer patients' first visit to the medical oncology unit to be informed about the possibility for entry into a clinical study (phase II or Phase III trial) with chemotherapy.

Patients who fulfilled the above criteria and had completed 12 weeks of treatment without evidence of disease progression or poor compliance to treatment, and with adequate tolerance of tazarotene, were eligible for entry into a follow-up study, subject to the exclusion criteria in the first part of the study and the provision of further signed informed consent.

Although known diabetes was an exclusion criterion for entry into the study, a small percentage of subjects had a fasting glucose or 2-h glucose in diabetic range (Table 1).

weeks is preferred for Phase 3 trials; (6) prior to entry into a negative symptom study, subjects should demonstrate clinical stability for a period of 4 to 6. months by collection of retrospective information; and (7) prior to entry, the stability of negative and positive symptoms should be confirmed prospectively for four weeks or longer.

The most significant was interval from the end of previous treatment to entry into a phase II study.

Other eligibility criteria included documented disease progression within 2 months prior to entry into the study, a World Health Organisation (WHO) performance status of 0 2, a life expectancy of >3 months, and adequate bone marrow, hepatic, and renal function.